Lifecare ASA

Report Publication Announcement • Oct 22, 2024

Lifecare ASA listed on Euronext Oslo Børs

Lifecare ASA listed on Euronext Oslo Børs

Bergen, Norway, 22 October 2024: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), has its first day of trading at Euronext Oslo Børs.

Reference is made to Lifecare's stock exchange announcement 21 September 2024,

announcing that Oslo Børs approved Lifecare's transfer from Euronext Growth to

Euronext Oslo Børs. Today, Lifecare's management and board of directors rang

the bell to mark the opening of the markets at Oslo Børs.

- Taking the step to the regulated market Euronext Oslo Børs is an important

milestone for Lifecare. On behalf of the entire organization, I am very proud

that Oslo Børs has assessed and concluded that Lifecare meets the conditions

for admission to the main list. We have proven the technology; we have focused

on setting up production and we are now approaching our first product.

Lifecare is ready for Euronext Oslo Børs, says CEO Joacim Holter at Lifecare

ASA.

The company has been listed on Euronext Growth since 2018. In February 2024

the board decided to apply for listing at Euronext Oslo Børs. Just eight

months later, the listing has become a reality.

- We have had a rapid development since we entered Euronext Growth six years

ago, and our organization has matured as we have prepared the company for

Euronext Oslo Børs. Over the past 3-4 years, the company has accelerated in

technology, production preparations, organizational development and

preparations for the commercialization phase, Holter adds.

Holter mentions that Lifecare has developed from a listed start-up company to

an international group with presence in Norway, Germany and England. Lifecare

has increased the staff from 2 in 2020 to approximately 35 employees today.

- We have streamlined our administrative operations, balancing cutting-edge

technological innovation with future commercialization efforts. I am

incredibly proud of the Lifecare team, who have worked tirelessly to bring us

to this point. Looking forward, I am excited for the future as we aim to

introduce the next generation of CGM-sensors to improve diabetes management

for humans and pets, says Holter.

- Diabetes is a pandemic of unprecedented magnitude spiralling out of control,

affecting hundreds of millions of people worldwide. Our ambition is to make

life easier, better, and more predictable for patients and pets with diabetes.

Lifecare is dedicated to developing the next generation of miniaturized and

implantable long-term Continuous Glucose Monitors to the market. Now, with the

listing at Euronext Oslo Børs, we are making Lifecare more accessible to

institutional and international investors, says Holter.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42